Liraglutide study to investigate dietary preferences and eating habits in Type 2 Diabetes patients

Managing Type 2 Diabetes (T2DM) often requires significant lifestyle changes, but adherence can be challenging due to complex eating behaviors. GLP-1 receptor agonists like Liraglutide are effective for glucose control and weight loss, partly by influencing central nervous system pathways related to appetite and satiety. However, the precise mechanisms by which Liraglutide alters the hedonic aspects of food (liking), the motivation to eat (wanting), and physiological responses such as salivation in T2DM patients are not fully elucidated. This study aims to specifically investigate these modifications.

This is an open-label comparative study designed with 90 participants divided into three parallel groups. Group 1 comprises 30 patients with Type 2 Diabetes indicated for GLP-1 analogue treatment, initiating Liraglutide (Victoza®). Group 2 includes 30 patients with Type 2 Diabetes not receiving incretin therapy (diabetic controls). Group 3 consists of 30 healthy subjects (non-diabetic controls). The study will assess modifications in eating behavior, specifically 'liking', 'wanting', and salivation in response to food presentation, with measurements taken at D0 (baseline), 15 days, 3 months, and 9 months (with varying participation across groups for follow-ups).